Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.32 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22020557 | 1.00 | NCF1 (0.44) | NCF1CYP1A2CYP2D6OPRK1KAT2B | |
| SCHEMBL8235125 | 1.00 | NCF1 (0.44) | NCF1CYP1A2CYP2D6OPRK1KAT2B | |
| SCHEMBL102076 | 0.88 | NCF1 (0.52) | NCF1OPRK1MEN1MITFKMT2A | |
| SCHEMBL19010154 | 0.86 | CHRM2 (0.38) | NCF1CYP2D6OPRK1KAT2BKAT2A | |
| SCHEMBL19010165 | 0.86 | CHRM2 (0.38) | NCF1CYP2D6OPRK1KAT2BKAT2A | |
| SCHEMBL9925436 | 0.86 | CHRM2 (0.38) | NCF1CYP2D6OPRK1KAT2BKAT2A | |
| SCHEMBL19122763 | 0.85 | CHRM5 (0.35) | CYP2D6OPRK1KAT2BCHRM2CHRM1 | |
| SCHEMBL30831689 | 0.84 | NCF1 (0.48) | NCF1CYP1A2CYP2D6CHRM2CHRM1 | |
| SCHEMBL22302354 | 0.82 | NCF1 (0.39) | NCF1OPRK1 | |
| SCHEMBL10154735 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021139748-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-15 | — | — | WO | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | KDM1A, KDM4A, KDM1B | NCF1 2944/4885CYP1A2 618/4885CYP2D6 713/4885 |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | KRAS, NRAS, HRAS | NCF1 2377/4885CYP1A2 1287/4885CYP2D6 333/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | NCF1 975/4885CYP1A2 162/4885CYP2D6 251/4885 |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | KRAS, NRAS, HRAS | NCF1 2377/4885CYP1A2 1287/4885CYP2D6 333/4885 |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | NCF1 2369/4885CYP1A2 2701/4885CYP2D6 1788/4885 |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NCF1 1125/4885CYP1A2 3378/4885CYP2D6 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.